HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LAEKNA-B

6.405

+0.3956.57%

Volume:7.77M

Turnover:48.16M

Market Cap:2.88B

PE:-10.86

High:6.405

Open:6.220

Low:5.705

Close:6.010

52wk High:19.600

52wk Low:5.370

Shares:449.00M

HK Float Shares:449.00M

Volume Ratio:4.63

T/O Rate:1.73%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.590

ROE:-10.69%

ROA:-7.60%

PB:2.06

PE(LYR):-10.86

PS:9.60

Loading ...

Overview Company News Filings

Laekna Grants 15.32 Million RSUs; Director Awards Require Shareholder Nod

Bulletin Express

LAEKNA-B (02105) Grants 15.3235 Million Restricted Share Units in Total

LAEKNA-B Shares Surge Over 5% in Late Trading as Qilu Pharma Advances Domestic Application for LAE002

Laekna-B Keeps Share Base Unchanged in April 2026; Public Float Remains Above 25%

Bulletin Express

Revised Title

Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial

MT Newswires Live

LAEKNA-B's Afuresertib Meets Primary Endpoint in Phase III Breast Cancer Trial

Laekna says phase III afuresertib breast cancer trial meets PFS endpoint

莱凯医药2025年实现首笔收入并稳步推进ActRII管线，研发投入上升净亏损收窄

Bulletin Express

Laekna publishes 2025 annual report

Weight-Loss Drug Market Competition Intensifies as Laekna's LAE102 Shows Superior Clinical Data Over Small RNA Therapies

Laekna-B Maintains 446.47 Million Outstanding Shares in March; No Capital Changes Reported

Bulletin Express

BRIEF-Laekna Posts FY Revenue Rmb106.7 Million

Laekna Narrows Loss in 2025

MT Newswires Live

LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%

Laekna FY2025 net loss narrows 9.8% to CNY229.32 million

Laekna Inc - Loss for Year RMB229.3 Mln

THOMSON REUTERS

Laekna Says Obesity Drug Shows Signs of Lean Body Mass, Reduced Fat in Women

MT Newswires Live

Laekna-B (02105.HK): Phase I U.S. SAD Study of LAE102 Delivers 5.06% Lean-Mass Gain and Fat-Mass Reduction Signals

Bulletin Express

LAEKNA-B (02105) Reports Encouraging Muscle-Building and Fat-Reducing Trends from US Phase I SAD Study of LAE102

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02105/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02105","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":6.405,"timestamp":1788163728004,"preClose":6.01,"halted":0,"volume":7772642,"delay":0,"changeRate":0.06572379367720474,"floatShares":449000000,"shares":449000000,"eps":-0.59,"marketStatus":"Closed","change":0.395,"latestTime":"08-31 16:08:48","open":6.22,"high":6.405,"low":5.705,"amount":48161832,"amplitude":0.116473,"askPrice":6.41,"askSize":500,"bidPrice":6.405,"bidSize":672500,"shortable":3,"etf":0,"ttmEps":-0.262,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":6.01,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":4.627123,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02105\",,,,,undefined,":{"symbol":"02105","floatShares":449000000,"roa":"-7.60%","roe":"-10.69%","lyrEps":-0.59,"volumeRatio":4.627123,"shares":449000000,"dividePrice":0,"high":6.405,"amplitude":0.116473,"preClose":6.01,"low":5.705,"week52Low":5.37,"pbRate":"2.06","psRate":"9.60","week52High":19.6,"institutionHeld":0,"latestPrice":6.405,"committee":0.998514,"eps":-0.59,"divideRate":0,"volume":7772642,"delay":0,"ttmEps":-0.262,"open":6.22,"prevYearClose":13.57,"prevWeekClose":6.01,"prevMonthClose":6.05,"prevQuarterClose":6.72,"fiveDayClose":6.365,"twentyDayClose":6.02,"sixtyDayClose":9.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02105\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"date":"2026-03-18","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1773797400000,"name":null,"time":"","dateTimestamp":1773763200000,"actualEps":null},{"date":"2025-08-13","symbol":"02105","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755048600000,"name":null,"time":"","dateTimestamp":1755014400000,"actualEps":null},{"date":"2025-03-24","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post-Mkt","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-16","symbol":"02105","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723771800000,"name":null,"time":"Post-Mkt","dateTimestamp":1723737600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02105\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02105\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1778256000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02105\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02105","date":"2026-08-28","current":-24.446565,"percent":0.242308,"low":-30.832985,"twenty":-22.291445,"median":-11.601008,"eighty":-6.147909,"high":-1.640852,"avg":-13.699372,"sd":7.897322,"marketCap":2544745305},"quantilePoints":[{"date":"2023-06-30","current":-7.785551,"twenty":-6.73679,"median":-5.163648,"eighty":-3.590506,"marketCap":6577091901},{"date":"2023-07-07","current":-6.912426,"twenty":-7.480081,"median":-7.023469,"eighty":-6.753459,"marketCap":5828099229},{"date":"2023-07-14","current":-6.415246,"twenty":-7.354402,"median":-6.80281,"eighty":-6.620389,"marketCap":5484810921},{"date":"2023-07-21","current":-6.50021,"twenty":-7.00126,"median":-6.637911,"eighty":-6.415921,"marketCap":5531622963},{"date":"2023-07-28","current":-6.387862,"twenty":-6.910347,"median":-6.626959,"eighty":-6.393338,"marketCap":5430196872},{"date":"2023-08-04","current":-6.872048,"twenty":-6.916775,"median":-6.645885,"eighty":-6.415921,"marketCap":5851505250},{"date":"2023-08-11","current":-8.062915,"twenty":-7.354402,"median":-6.732662,"eighty":-6.423028,"marketCap":6826756125},{"date":"2023-08-18","current":-6.496848,"twenty":-7.428921,"median":-6.729682,"eighty":-6.45189,"marketCap":5461404900},{"date":"2023-08-25","current":-8.440637,"twenty":-7.525288,"median":-6.804775,"eighty":-6.49752,"marketCap":6327427677},{"date":"2023-09-01","current":-9.089804,"twenty":-8.007442,"median":-6.902032,"eighty":-6.501491,"marketCap":6842360139},{"date":"2023-09-08","current":-6.586545,"twenty":-8.136633,"median":-6.907229,"eighty":-6.507456,"marketCap":4899660396},{"date":"2023-09-15","current":-5.932237,"twenty":-8.007442,"median":-6.869978,"eighty":-6.423028,"marketCap":4447143990},{"date":"2023-09-22","current":-6.606383,"twenty":-7.784235,"median":-6.883282,"eighty":-6.45189,"marketCap":4930868424},{"date":"2023-09-29","current":-7.14814,"twenty":-7.744431,"median":-6.894516,"eighty":-6.45189,"marketCap":5344374795},{"date":"2023-10-06","current":-7.631816,"twenty":-7.631816,"median":-6.912426,"eighty":-6.496848,"marketCap":5703267117},{"date":"2023-10-13","current":-8.856112,"twenty":-8.155063,"median":-6.923868,"eighty":-6.50021,"marketCap":6608299929},{"date":"2023-10-20","current":-8.199572,"twenty":-8.313082,"median":-7.000277,"eighty":-6.506614,"marketCap":6108971481},{"date":"2023-10-27","current":-9.816471,"twenty":-8.453817,"median":-7.029823,"eighty":-6.509983,"marketCap":7310480559},{"date":"2023-11-03","current":-11.65035,"twenty":-8.539495,"median":-7.190868,"eighty":-6.562195,"marketCap":8699237805},{"date":"2023-11-10","current":-10.973476,"twenty":-8.805599,"median":-7.285091,"eighty":-6.584244,"marketCap":8192107350},{"date":"2023-11-17","current":-11.729885,"twenty":-9.08956,"median":-7.4166,"eighty":-6.600627,"marketCap":8835772927},{"date":"2023-11-24","current":-11.685472,"twenty":-9.394133,"median":-7.490817,"eighty":-6.605936,"marketCap":8874782962},{"date":"2023-12-01","current":-9.84176,"twenty":-10.15546,"median":-7.577915,"eighty":-6.610422,"marketCap":7505530734},{"date":"2023-12-08","current":-7.796477,"twenty":-9.900606,"median":-7.778973,"eighty":-6.615093,"marketCap":5921723313},{"date":"2023-12-15","current":-9.518573,"twenty":-9.821529,"median":-7.782262,"eighty":-6.63353,"marketCap":7271470524},{"date":"2023-12-22","current":-9.095699,"twenty":-9.838318,"median":-7.864399,"eighty":-6.64429,"marketCap":6943786230},{"date":"2023-12-29","current":-10.114857,"twenty":-10.007865,"median":-8.108989,"eighty":-6.673018,"marketCap":7762996965},{"date":"2024-01-05","current":-7.064143,"twenty":-9.846254,"median":-7.963657,"eighty":-6.71691,"marketCap":5383384830},{"date":"2024-01-12","current":-6.507833,"twenty":-9.8409,"median":-7.785551,"eighty":-6.71691,"marketCap":4962076452},{"date":"2024-01-19","current":-6.147909,"twenty":-9.833261,"median":-7.674627,"eighty":-6.639506,"marketCap":4681204200},{"date":"2024-01-26","current":-4.037471,"twenty":-9.789285,"median":-7.606263,"eighty":-6.604594,"marketCap":3062287747},{"date":"2024-02-02","current":-1.910591,"twenty":-9.668744,"median":-7.523229,"eighty":-6.508431,"marketCap":1447272298},{"date":"2024-02-09","current":-1.972972,"twenty":-9.600955,"median":-7.449769,"eighty":-6.45189,"marketCap":1501886347},{"date":"2024-02-16","current":-2.11088,"twenty":-9.539168,"median":-7.4166,"eighty":-6.417948,"marketCap":1607213442},{"date":"2024-02-23","current":-1.782124,"twenty":-9.334553,"median":-7.285091,"eighty":-6.285716,"marketCap":1349747211},{"date":"2024-03-01","current":-3.73704,"twenty":-9.184661,"median":-7.220535,"eighty":-6.16588,"marketCap":2832128541},{"date":"2024-03-08","current":-3.812556,"twenty":-9.158571,"median":-7.14814,"eighty":-5.783471,"marketCap":2890643593},{"date":"2024-03-15","current":-3.774736,"twenty":-9.108268,"median":-7.054895,"eighty":-5.122231,"marketCap":2859435565},{"date":"2024-03-22","current":-3.314294,"twenty":-9.090983,"median":-7.029823,"eighty":-4.16949,"marketCap":2508345250},{"date":"2024-03-28","current":-5.557677,"twenty":-9.089621,"median":-7.000277,"eighty":-4.108477,"marketCap":2219670991},{"date":"2024-04-05","current":-4.994454,"twenty":-9.061533,"median":-6.958518,"eighty":-4.159233,"marketCap":1993412788},{"date":"2024-04-12","current":-4.698569,"twenty":-8.939101,"median":-6.914215,"eighty":-4.187247,"marketCap":1876382683},{"date":"2024-04-19","current":-5.074098,"twenty":-8.895252,"median":-6.907229,"eighty":-4.270544,"marketCap":2024620816},{"date":"2024-04-26","current":-6.049449,"twenty":-8.886537,"median":-6.872048,"eighty":-4.439166,"marketCap":2410820163},{"date":"2024-05-03","current":-6.122202,"twenty":-8.8768,"median":-6.815159,"eighty":-4.698569,"marketCap":2438127187},{"date":"2024-05-10","current":-6.43996,"twenty":-8.86224,"median":-6.755587,"eighty":-4.994454,"marketCap":2570761306},{"date":"2024-05-17","current":-7.203002,"twenty":-8.857338,"median":-6.782134,"eighty":-5.0499,"marketCap":2871138576},{"date":"2024-05-24","current":-4.794357,"twenty":-8.851703,"median":-6.739573,"eighty":-4.885401,"marketCap":2754108471},{"date":"2024-05-31","current":-4.572395,"twenty":-8.804497,"median":-6.721699,"eighty":-4.757241,"marketCap":2629276359},{"date":"2024-06-07","current":-4.421848,"twenty":-8.685949,"median":-6.645885,"eighty":-4.615745,"marketCap":2539553278},{"date":"2024-06-14","current":-3.882014,"twenty":-8.64394,"median":-6.616008,"eighty":-4.537135,"marketCap":2227472998},{"date":"2024-06-21","current":-3.862906,"twenty":-8.598267,"median":-6.605265,"eighty":-4.402835,"marketCap":2211868984},{"date":"2024-06-28","current":-3.550986,"twenty":-8.56584,"median":-6.575038,"eighty":-4.108477,"marketCap":2032422823},{"date":"2024-07-05","current":-3.292704,"twenty":-8.553381,"median":-6.507833,"eighty":-3.906941,"marketCap":1884184690},{"date":"2024-07-12","current":-3.669077,"twenty":-8.541472,"median":-6.498529,"eighty":-3.863311,"marketCap":2102640886},{"date":"2024-07-19","current":-2.927038,"twenty":-8.530589,"median":-6.44065,"eighty":-3.81922,"marketCap":1677431505},{"date":"2024-07-26","current":-2.773786,"twenty":-8.516747,"median":-6.41868,"eighty":-3.760814,"marketCap":1595510431},{"date":"2024-08-02","current":-3.12148,"twenty":-8.510893,"median":-6.387862,"eighty":-3.652511,"marketCap":1794461610},{"date":"2024-08-09","current":-2.9997,"twenty":-8.480176,"median":-6.325017,"eighty":-3.53511,"marketCap":1735946557},{"date":"2024-08-16","current":-3.214159,"twenty":-8.413826,"median":-6.28512,"eighty":-3.427,"marketCap":1860778669},{"date":"2024-08-23","current":-6.604067,"twenty":-8.372166,"median":-6.272718,"eighty":-3.478589,"marketCap":2129947911},{"date":"2024-08-30","current":-6.163541,"twenty":-8.347233,"median":-6.28512,"eighty":-3.497821,"marketCap":2001214795},{"date":"2024-09-06","current":-5.314921,"twenty":-8.300967,"median":-6.252611,"eighty":-3.516857,"marketCap":1726510663},{"date":"2024-09-13","current":-5.032211,"twenty":-8.277822,"median":-6.194778,"eighty":-3.53511,"marketCap":1630395636},{"date":"2024-09-20","current":-5.111432,"twenty":-8.256206,"median":-6.170373,"eighty":-3.56099,"marketCap":1665993794},{"date":"2024-09-27","current":-6.057967,"twenty":-8.195708,"median":-6.135055,"eighty":-3.605108,"marketCap":1986377216},{"date":"2024-10-04","current":-7.03444,"twenty":-8.180254,"median":-6.166957,"eighty":-3.621517,"marketCap":2296081191},{"date":"2024-10-10","current":-6.311883,"twenty":-8.160101,"median":-6.193894,"eighty":-3.641637,"marketCap":2046894085},{"date":"2024-10-18","current":-9.026405,"twenty":-8.160101,"median":-6.241014,"eighty":-3.658355,"marketCap":2911929324},{"date":"2024-10-25","current":-10.329157,"twenty":-8.288852,"median":-6.25781,"eighty":-3.667517,"marketCap":3331987588},{"date":"2024-11-01","current":-10.068556,"twenty":-8.453817,"median":-6.28512,"eighty":-3.723447,"marketCap":3250111825},{"date":"2024-11-08","current":-11.890039,"twenty":-8.539495,"median":-6.303819,"eighty":-3.748634,"marketCap":3809002906},{"date":"2024-11-15","current":-12.473246,"twenty":-8.638855,"median":-6.337113,"eighty":-3.770095,"marketCap":3965634801},{"date":"2024-11-22","current":-15.548537,"twenty":-8.857338,"median":-6.401271,"eighty":-3.792036,"marketCap":4941024330},{"date":"2024-11-29","current":-16.918042,"twenty":-8.907392,"median":-6.418623,"eighty":-3.798946,"marketCap":5372620800},{"date":"2024-12-06","current":-17.028741,"twenty":-9.08956,"median":-6.440305,"eighty":-3.809963,"marketCap":5395037855},{"date":"2024-12-13","current":-14.037501,"twenty":-9.184661,"median":-6.496848,"eighty":-3.825885,"marketCap":4438576850},{"date":"2024-12-20","current":-10.693671,"twenty":-9.519989,"median":-6.507224,"eighty":-3.843767,"marketCap":3366294395},{"date":"2024-12-27","current":-10.761363,"twenty":-9.613258,"median":-6.510825,"eighty":-3.853605,"marketCap":3384975274},{"date":"2025-01-03","current":-12.815569,"twenty":-9.789285,"median":-6.563121,"eighty":-3.862906,"marketCap":4035069864},{"date":"2025-01-10","current":-14.889249,"twenty":-9.925093,"median":-6.595306,"eighty":-3.863109,"marketCap":4670219750},{"date":"2025-01-17","current":-11.842286,"twenty":-10.213871,"median":-6.606383,"eighty":-3.864484,"marketCap":3717494921},{"date":"2025-01-24","current":-10.786847,"twenty":-10.358151,"median":-6.624251,"eighty":-3.867614,"marketCap":3407392329},{"date":"2025-01-28","current":-10.88357,"twenty":-10.395234,"median":-6.635203,"eighty":-3.869357,"marketCap":3455962615},{"date":"2025-02-07","current":-10.247352,"twenty":-10.395234,"median":-6.668158,"eighty":-3.877648,"marketCap":3235528242},{"date":"2025-02-14","current":-10.714001,"twenty":-10.679993,"median":-6.721699,"eighty":-3.919404,"marketCap":3381239099},{"date":"2025-02-21","current":-14.934496,"twenty":-10.737429,"median":-6.739573,"eighty":-3.995096,"marketCap":4729998562},{"date":"2025-02-28","current":-14.81818,"twenty":-10.833722,"median":-6.801774,"eighty":-4.034059,"marketCap":4677692101},{"date":"2025-03-07","current":-17.375919,"twenty":-11.045086,"median":-6.869978,"eighty":-4.108477,"marketCap":5507123129},{"date":"2025-03-14","current":-16.002657,"twenty":-11.141514,"median":-6.898274,"eighty":-4.166071,"marketCap":5073726736},{"date":"2025-03-21","current":-15.584553,"twenty":-11.292034,"median":-6.914215,"eighty":-4.215924,"marketCap":4939224407},{"date":"2025-03-28","current":-19.960729,"twenty":-11.418322,"median":-6.958518,"eighty":-4.322429,"marketCap":5432399613},{"date":"2025-04-03","current":-17.71685,"twenty":-11.522026,"median":-7.011873,"eighty":-4.393328,"marketCap":4812194430},{"date":"2025-04-11","current":-14.733536,"twenty":-11.702518,"median":-7.03444,"eighty":-4.445369,"marketCap":3975291051},{"date":"2025-04-17","current":-15.831036,"twenty":-11.83884,"median":-7.042573,"eighty":-4.481028,"marketCap":4281657466},{"date":"2025-04-25","current":-18.85387,"twenty":-11.890039,"median":-7.064143,"eighty":-4.482534,"marketCap":5103616142},{"date":"2025-05-02","current":-20.273816,"twenty":-12.024603,"median":-7.138152,"eighty":-4.483904,"marketCap":5499650777},{"date":"2025-05-09","current":-20.37867,"twenty":-12.272607,"median":-7.171338,"eighty":-4.537135,"marketCap":5566901942},{"date":"2025-05-16","current":-19.209634,"twenty":-12.535336,"median":-7.205238,"eighty":-4.575802,"marketCap":5290424932},{"date":"2025-05-23","current":-24.021586,"twenty":-12.71305,"median":-7.273665,"eighty":-4.590948,"marketCap":6635448220},{"date":"2025-05-30","current":-24.266566,"twenty":-12.811921,"median":-7.298393,"eighty":-4.611692,"marketCap":6732588791},{"date":"2025-06-06","current":-26.139049,"twenty":-13.04892,"median":-7.396066,"eighty":-4.640938,"marketCap":7270598106},{"date":"2025-06-13","current":-29.74055,"twenty":-13.19671,"median":-7.470293,"eighty":-4.681154,"marketCap":8275629397},{"date":"2025-06-20","current":-28.050034,"twenty":-13.86335,"median":-7.533906,"eighty":-4.700982,"marketCap":7789926543},{"date":"2025-06-27","current":-24.148232,"twenty":-14.651862,"median":-7.597268,"eighty":-4.71884,"marketCap":6725116440},{"date":"2025-07-04","current":-23.234874,"twenty":-14.895898,"median":-7.634748,"eighty":-4.738772,"marketCap":6471056485},{"date":"2025-07-11","current":-22.291445,"twenty":-15.089879,"median":-7.696392,"eighty":-4.760215,"marketCap":6202051828},{"date":"2025-07-18","current":-26.31753,"twenty":-15.471722,"median":-7.782262,"eighty":-4.775945,"marketCap":7316474020},{"date":"2025-07-25","current":-25.476909,"twenty":-15.613487,"median":-7.864399,"eighty":-4.786942,"marketCap":7108532126},{"date":"2025-08-01","current":-24.329935,"twenty":-15.664049,"median":-8.108989,"eighty":-4.797184,"marketCap":6746559201},{"date":"2025-08-08","current":-25.903798,"twenty":-15.966112,"median":-8.199572,"eighty":-4.803824,"marketCap":7200950746},{"date":"2025-08-15","current":-26.404653,"twenty":-16.351868,"median":-8.297938,"eighty":-4.809409,"marketCap":6923694888},{"date":"2025-08-22","current":-24.957996,"twenty":-16.76437,"median":-8.37361,"eighty":-4.821672,"marketCap":6523837408},{"date":"2025-08-29","current":-23.625619,"twenty":-17.081215,"median":-8.510167,"eighty":-4.847599,"marketCap":6205046052},{"date":"2025-09-05","current":-24.661552,"twenty":-17.4013,"median":-8.538507,"eighty":-4.876556,"marketCap":6470705516},{"date":"2025-09-12","current":-20.300804,"twenty":-17.709582,"median":-8.5673,"eighty":-4.894937,"marketCap":5336119539},{"date":"2025-09-19","current":-22.387755,"twenty":-18.502396,"median":-8.659194,"eighty":-4.936492,"marketCap":5880503891},{"date":"2025-09-26","current":-23.755076,"twenty":-18.883269,"median":-8.853357,"eighty":-5.007141,"marketCap":6223463577},{"date":"2025-10-03","current":-26.75639,"twenty":-19.317505,"median":-8.86952,"eighty":-5.027379,"marketCap":7026491136},{"date":"2025-10-10","current":-24.099943,"twenty":-19.58973,"median":-8.892896,"eighty":-5.032211,"marketCap":6319659587},{"date":"2025-10-17","current":-21.756329,"twenty":-19.863851,"median":-8.951685,"eighty":-5.039347,"marketCap":5700659177},{"date":"2025-10-24","current":-19.051807,"twenty":-20.078316,"median":-9.089652,"eighty":-5.055065,"marketCap":4993827628},{"date":"2025-10-31","current":-18.736648,"twenty":-20.048899,"median":-9.127121,"eighty":-5.062023,"marketCap":4918543795},{"date":"2025-11-07","current":-16.723664,"twenty":-19.976892,"median":-9.288548,"eighty":-5.072031,"marketCap":4387374524},{"date":"2025-11-14","current":-21.334357,"twenty":-19.976892,"median":-9.450099,"eighty":-5.103965,"marketCap":5612828038},{"date":"2025-11-21","current":-24.191268,"twenty":-20.149,"median":-9.60082,"eighty":-5.127222,"marketCap":6361483939},{"date":"2025-11-28","current":-26.084626,"twenty":-20.359324,"median":-9.675041,"eighty":-5.135712,"marketCap":6884288339},{"date":"2025-12-05","current":-26.466998,"twenty":-20.455357,"median":-9.837458,"eighty":-5.145701,"marketCap":6997214089},{"date":"2025-12-12","current":-24.949582,"twenty":-21.347937,"median":-9.89595,"eighty":-5.163276,"marketCap":6608247616},{"date":"2025-12-19","current":-24.323785,"twenty":-21.641075,"median":-10.068556,"eighty":-5.198656,"marketCap":6457679948},{"date":"2025-12-24","current":-21.98676,"twenty":-21.77214,"median":-10.125423,"eighty":-5.211333,"marketCap":5855409280},{"date":"2026-01-02","current":-21.259193,"twenty":-21.755726,"median":-10.240347,"eighty":-5.219085,"marketCap":5683929436},{"date":"2026-01-09","current":-20.81628,"twenty":-21.755726,"median":-10.329157,"eighty":-5.237411,"marketCap":5579368556},{"date":"2026-01-16","current":-22.553102,"twenty":-21.77741,"median":-10.348222,"eighty":-5.302498,"marketCap":6064531040},{"date":"2026-01-23","current":-24.816667,"twenty":-21.782791,"median":-10.364083,"eighty":-5.307592,"marketCap":6666801708},{"date":"2026-01-30","current":-21.232192,"twenty":-21.93483,"median":-10.54642,"eighty":-5.31773,"marketCap":5729936224},{"date":"2026-02-06","current":-19.168838,"twenty":-21.847156,"median":-10.680397,"eighty":-5.331073,"marketCap":5186219648},{"date":"2026-02-13","current":-19.151587,"twenty":-21.790077,"median":-10.7243,"eighty":-5.344782,"marketCap":5211314259},{"date":"2026-02-20","current":-20.225911,"twenty":-21.786448,"median":-10.738136,"eighty":-5.355348,"marketCap":5495719852},{"date":"2026-02-27","current":-20.250109,"twenty":-21.782736,"median":-10.786847,"eighty":-5.38165,"marketCap":5562638816},{"date":"2026-03-06","current":-19.984902,"twenty":-21.771543,"median":-10.928523,"eighty":-5.410462,"marketCap":5445530630},{"date":"2026-03-13","current":-22.811571,"twenty":-21.771543,"median":-11.041852,"eighty":-5.454036,"marketCap":6244375753},{"date":"2026-03-20","current":-23.005636,"twenty":-21.897901,"median":-11.062683,"eighty":-5.524583,"marketCap":6273652800},{"date":"2026-03-27","current":-24.70918,"twenty":-21.969868,"median":-11.156828,"eighty":-5.583337,"marketCap":6415855596},{"date":"2026-04-02","current":-26.739107,"twenty":-22.031812,"median":-11.209207,"eighty":-5.601063,"marketCap":6976301913},{"date":"2026-04-10","current":-28.538856,"twenty":-22.291445,"median":-11.292041,"eighty":-5.601991,"marketCap":7503288748},{"date":"2026-04-17","current":-29.020205,"twenty":-22.432658,"median":-11.346073,"eighty":-5.604798,"marketCap":7633046388},{"date":"2026-04-24","current":-25.005525,"twenty":-22.553999,"median":-11.464969,"eighty":-5.642769,"marketCap":6577457052},{"date":"2026-04-30","current":-22.649452,"twenty":-22.652659,"median":-11.521828,"eighty":-5.657293,"marketCap":5959243378},{"date":"2026-05-08","current":-21.503881,"twenty":-22.608665,"median":-11.665703,"eighty":-5.750774,"marketCap":5677472520},{"date":"2026-05-15","current":-23.576331,"twenty":-22.667669,"median":-11.721884,"eighty":-5.808834,"marketCap":6241014236},{"date":"2026-05-22","current":-20.971126,"twenty":-22.652659,"median":-11.842286,"eighty":-5.818464,"marketCap":5538689858},{"date":"2026-05-29","current":-18.548518,"twenty":-22.618862,"median":-11.887088,"eighty":-5.822043,"marketCap":4915889017},{"date":"2026-06-05","current":-15.889363,"twenty":-22.592312,"median":-11.941645,"eighty":-5.861291,"marketCap":4217248459},{"date":"2026-06-12","current":-15.10192,"twenty":-22.567683,"median":-12.13498,"eighty":-5.892489,"marketCap":4005539199},{"date":"2026-06-18","current":-12.039878,"twenty":-22.55364,"median":-12.220984,"eighty":-5.903768,"marketCap":3201044011},{"date":"2026-06-26","current":-9.954438,"twenty":-22.542516,"median":-12.018444,"eighty":-5.921382,"marketCap":2633663194},{"date":"2026-07-03","current":-12.473726,"twenty":-22.516485,"median":-11.971842,"eighty":-5.93398,"marketCap":3302664456},{"date":"2026-07-10","current":-11.800553,"twenty":-22.467229,"median":-11.890039,"eighty":-5.95812,"marketCap":3120594492},{"date":"2026-07-17","current":-10.338728,"twenty":-22.427368,"median":-11.878246,"eighty":-6.031304,"marketCap":2743752009},{"date":"2026-07-24","current":-10.336405,"twenty":-22.402517,"median":-11.842286,"eighty":-6.049385,"marketCap":2743752009},{"date":"2026-07-31","current":-9.632203,"twenty":-22.387755,"median":-11.800553,"eighty":-6.049449,"marketCap":2561682046},{"date":"2026-08-07","current":-11.146935,"twenty":-22.37885,"median":-11.702001,"eighty":-6.057967,"marketCap":2970280917},{"date":"2026-08-14","current":-11.109037,"twenty":-22.376311,"median":-11.665703,"eighty":-6.076766,"marketCap":2963929640},{"date":"2026-08-21","current":-9.58021,"twenty":-22.291445,"median":-11.592106,"eighty":-6.122202,"marketCap":2561682046},{"date":"2026-08-28","current":-21.342999,"twenty":-22.291445,"median":-11.601008,"eighty":-6.147909,"marketCap":2544745305}],"updateTime":1788184194978},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02105\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1163365766","title":"Laekna Grants 15.32 Million RSUs; Director Awards Require Shareholder Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=1163365766","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163365766?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:43","pubTimestamp":1778240631,"startTime":"0","endTime":"0","summary":"Laekna-B has approved the issuance of 15.32 million restricted share units (RSUs) under its 2024 Share Award Scheme, according to a board announcement dated 8 May 2026. Key grant parameters   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176480621","title":"LAEKNA-B (02105) Grants 15.3235 Million Restricted Share Units in Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1176480621","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176480621?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:39","pubTimestamp":1778240345,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that on May 8, 2026, a total of 15.3235 million restricted share units, equivalent to 15.3235 million shares, were granted to recipients under the 2024 Share Award Scheme....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145594989","title":"LAEKNA-B Shares Surge Over 5% in Late Trading as Qilu Pharma Advances Domestic Application for LAE002","url":"https://stock-news.laohu8.com/highlight/detail?id=1145594989","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145594989?lang=en_us&edition=fundamental","pubTime":"2026-05-07 15:26","pubTimestamp":1778138779,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) saw its shares rise more than 5% in late trading. As of the time of writing, the stock was up 3.83%, trading at HK$13.82 with a turnover of HK$25.91 million. On April 30, Qilu...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105","BK4585","BK1191","BK4588","01477","VXUS","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179282629","title":"Laekna-B Keeps Share Base Unchanged in April 2026; Public Float Remains Above 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179282629","media":"Bulletin Express","labels":["shareholding","SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179282629?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059434,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (abbrev. Laekna-B) reported no changes to its share capital structure for the month ended 30 April 2026, according to the company’s monthly return filed with Hong Kong Exchanges and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150443811","title":"Revised Title","url":"https://stock-news.laohu8.com/highlight/detail?id=1150443811","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150443811?lang=en_us&edition=fundamental","pubTime":"2026-04-20 09:56","pubTimestamp":1776650198,"startTime":"0","endTime":"0","summary":"CICC Maintains Outperform Rating on LAIKNA-B (02105) with HK$27.02 Target Price","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627477078","title":"Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627477078","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627477078?lang=en_us&edition=fundamental","pubTime":"2026-04-15 12:34","pubTimestamp":1776227646,"startTime":"0","endTime":"0","summary":"Laekna  said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103233133","title":"LAEKNA-B's Afuresertib Meets Primary Endpoint in Phase III Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1103233133","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103233133?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:26","pubTimestamp":1776212787,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced that its Phase III clinical trial, AFFIRM-205, evaluating LAE 002 (afuresertib) in combination with fulvestrant, has achieved strong positive topline results. The trial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK4134","BK4211","PFS","BK4195","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473859","title":"Laekna says phase III afuresertib breast cancer trial meets PFS endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473859","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473859?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:15","pubTimestamp":1776212144,"startTime":"0","endTime":"0","summary":"Laekna reported positive topline Phase III results for LAE002  with fulvestrant in HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA/AKT1/PTEN alterations.Trial met primary endpoint, showing a clinically meaningful delay in disease progression versus control.Safety profile remained consistent with earlier studies, with low treatment discontinuation due to adverse events.Detailed results will be presented at a future international scientific conference.Laekna plans near-term NDA submission in China with Qilu Pharma, supported by a China license deal worth up to RMB 2 billion in upfront and milestone payments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3vC8Qj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163097580","title":"莱凯医药2025年实现首笔收入并稳步推进ActRII管线，研发投入上升净亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1163097580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163097580?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:45","pubTimestamp":1776073500,"startTime":"0","endTime":"0","summary":"莱凯医药（于香港联交所主板上市，股票简称“LAEKNA-B”，股份代号02105）公布截至2025年12月31日止年度业绩，首次录得收入人民币1.067亿元（2024年无收入），主要来自向本地医药企业对LAE002（afuresertib）的许可交易。同期成本为人民币0.203亿元，毛利达人民币0.864亿元，毛利率为81.0%。研发开支同比增长16.2%至人民币2.499亿元，主要投向ActRI...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627436753","title":"Laekna publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2627436753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627436753?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:28","pubTimestamp":1776072502,"startTime":"0","endTime":"0","summary":"Laekna published 2025 annual report dated March 18, 2026, highlighting pipeline progress in obesity and oncology programs.Phase I SAD and MAD studies of LAE102 in China completed in 2025, supporting continued development as muscle-preserving weight-control therapy.LAE102 Phase I SAD study in US completed with Eli Lilly in March 2026, showing dose-dependent lean mass gains.Phase III AFFIRM-205 trial in China for LAE002 afuresertib with fulvestrant completed enrollment in December 2025, with topline data targeted in first half of 2026.Exclusive China-region license for LAE002 granted to Qilu Pharma, including milestone payments up to RMB 2.045 billion plus tiered royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. publi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4s28Gj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRY28.SGD","LU0820561818.USD","IE00BFSS8Q28.SGD","IE0009355771.USD","SG9999018857.SGD","LU0225283273.USD","LU0471298694.HKD","LU0353189763.USD","LU1267930730.SGD","SG9999014898.SGD","LU1989771016.USD","LU2237443549.SGD","SG9999014880.SGD","LU0882574055.USD","LU2491049909.HKD","LLYX","LU0882574139.USD","LU0316494557.USD","LU1366192091.USD","LU1868836757.USD","LU2237443622.USD","LU2168563687.JPY","IE00BJLML261.HKD","LU0964807845.USD","LU0058720904.USD","LU1804176565.USD","IE00BN29S564.USD","LU1712237335.SGD","LU2417539215.USD","BK4581","LU0079474960.USD","LU0109391861.USD","LU2089284900.SGD","LU1280957306.USD","LU2168564222.USD","IE00BJT1NW94.SGD","LU0094547139.USD","LU0820562030.AUD","LU2265009873.SGD","LU2491050154.USD","SG9999015978.USD","LU2324357040.USD","LU2602419157.SGD","SGXZ81514606.USD","LU0289739699.SGD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","IE00B1BXHZ80.USD","LU2461242641.AUD","IE0005OL40V9.USD","LU2471134523.USD","LU1623119135.USD","LU2023251221.USD","LU2237438978.USD","GB00BDT5M118.USD","LU0672654240.SGD","IE00BJJMRX11.SGD","LU2357305700.SGD","LU2756315318.SGD","LU2896262040.SGD","LU2237443382.USD","LU1548497426.USD","LU1720051108.HKD","LU2237443465.HKD","SG9999015945.SGD","LU0238689110.USD","LU0320765059.SGD","LU1551013342.USD","BK4007","LU2089984988.USD","LU0456855351.SGD","LU0823434583.USD","LU2168564495.EUR","LU2106854487.HKD","SGXZ57979304.SGD","SGXZ31699556.SGD","LU0708995401.HKD","BK4516","SG9999001176.USD","SGXZ99366536.SGD","LU2108987350.USD","LU2087625088.SGD","LU2552382215.SGD","LU0683600562.USD","LU0354030438.USD","LU2756315664.SGD","LU0385154629.USD","LU0689472784.USD","LU2211815571.USD","LU2264538146.SGD","IE00BJJMRZ35.SGD","LU0256863902.USD","LU2750360641.GBP","IE00B7KXQ091.USD","LU2471134796.USD","LU0889565916.HKD","IE0001KFT4U8.USD","SG9999014906.USD","IE00B4JS1V06.HKD","LU0006306889.USD","LU0234572021.USD","IE0002141913.USD","LU0787776722.HKD","LU2552382132.HKD","LLYZ","LU2360106947.USD","SG9999015952.SGD","LU2471134879.HKD","LLII","IE00BFTCPJ56.SGD","BK4585","IE00B1XK9C88.USD","LU1323610961.USD","LU0823434740.USD","LU2468319806.SGD","IE00BK4W5L77.USD","LU0417517546.SGD","LU1145028129.USD","LU1868836591.USD","LU0471298777.SGD","LU2552382058.USD","BK4588","LU2462157665.USD","LU1974910355.USD","LU2213496289.HKD","LU1629891620.HKD","LU2471134952.CNY","LU0786609619.USD","LU0354030511.USD","LU0158827781.USD","SG9999018865.SGD","LU2111349929.HKD","IE00BKDWB100.SGD","LU2089283258.USD","LU2746668974.SGD","SGXZ51526630.SGD","LU1814569148.SGD","LU0323591593.USD","LU1868837136.USD","LU1069344957.HKD","LU2491050071.SGD","LU2237443978.SGD","SG9999015986.USD","LU1868837300.USD","LU1917777945.USD","LU0203202063.USD","SG9999013999.USD","LU2168564065.EUR","LU2361044865.SGD","LU2746668461.USD","BK1161","LU0256863811.USD","SG9999017495.SGD","02105","LU0353189680.USD","LU1023059063.AUD","LU0158827948.USD","LU2237443895.HKD","LU1720051017.SGD","LU0210536198.USD","LU1988902786.USD","LU0466842654.USD","LU0106261372.USD","LU1983299246.USD","IE00BWXC8680.SGD","LU0198837287.USD","LU2236285917.USD","LU2271345857.HKD","LU0320765992.SGD","LU2361045086.USD","IE0004445239.USD","LU0266013472.USD","LU2023250504.SGD","LU1291159041.SGD","LU1127390331.HKD","LU0432979614.USD","LU2023250330.USD","LU0097036916.USD","ELIL","LU1551013425.SGD","LU0114720955.EUR","LU1093756325.SGD","BK4534","IE00BFSS7M15.SGD","LU0943347566.SGD","IE00B775H168.HKD","LU2168564149.EUR","LU0109394709.USD","IE0004445015.USD","BK4599","LU1064131342.USD","LU1093756168.USD","LU0061475181.USD","LU2028103732.USD","LU0823416689.USD","LU1061106388.HKD","LU1868836914.USD","BK4533","IE00BKPKM429.USD","SG9999001176.SGD","LU2361044949.HKD","LU1232071149.USD","LU2112291526.USD","LU2750360997.AUD","LU0096364046.USD","ELIS","LU0820561909.HKD","LU1057294990.SGD","LU2063271972.USD","LU0203201768.USD","LU1035775433.USD","IE00B4R5TH58.HKD","SG9999014914.USD","LU0122379950.USD","LU2456880835.USD","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197564420","title":"Weight-Loss Drug Market Competition Intensifies as Laekna's LAE102 Shows Superior Clinical Data Over Small RNA Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1197564420","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197564420?lang=en_us&edition=fundamental","pubTime":"2026-04-09 11:23","pubTimestamp":1775704981,"startTime":"0","endTime":"0","summary":"Laekna's core product LAE102 has demonstrated outstanding muscle-building effects and safety in its US Phase I clinical trial, surpassing small RNA-based weight-loss drug pipelines that have recently...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185906956","title":"Laekna-B Maintains 446.47 Million Outstanding Shares in March; No Capital Changes Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=1185906956","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185906956?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:27","pubTimestamp":1775122027,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Laekna-B (Laekna, Inc.) reported zero movement in both authorised and issued share capital. Authorised Share Capital   • Total authorised shares remained at 5.00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620025065","title":"BRIEF-Laekna Posts FY Revenue Rmb106.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620025065","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620025065?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:29","pubTimestamp":1773847744,"startTime":"0","endTime":"0","summary":"BRIEF-Laekna Posts FY Revenue Rmb106.7 MillionMarch 18 (Reuters) - Laekna Inc 2105.HK:FY REVENUE RMB106.7 MILLIONLOSS FOR YEAR RMB229.3 MILLIONFurther company coverage: 2105.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620820258","title":"Laekna Narrows Loss in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620820258","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620820258?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:36","pubTimestamp":1773833818,"startTime":"0","endTime":"0","summary":"Laekna  narrowed its loss to 229.3 million yuan for the year 2025 from 254.3 million yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharmaceutical company's loss per share stood at 0.59 yuan, compared with 0.71 yuan in the previous fiscal year.The firm recorded a revenue of 106.7 million yuan in the year, whereas no revenue was seen in the previous year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175483077","title":"LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175483077","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175483077?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:58","pubTimestamp":1773831501,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620321912","title":"Laekna FY2025 net loss narrows 9.8% to CNY229.32 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620321912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620321912?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830590,"startTime":"0","endTime":"0","summary":"Laekna published an annual results announcement for FY 2025, reporting revenue of RMB106.72 million and gross profit of RMB86.42 million. FY 2025 loss for the year narrowed 9.82% to RMB229.32 million, while total comprehensive loss widened 5.51% to RMB253.71 million. R&D expenses rose 16.2% to RMB249.9 million, which Laekna attributed mainly to higher spending on its ActRII portfolio  and increased equity-settled share-based payment expenses. Cash and bank balances increased 95.3% to RMB1.24 billion, and bank loans rose 18.58% to RMB117.41 million. On the pipeline, Laekna said Phase III recruitment for LAE002 plus fulvestrant  in China was completed, with topline data targeted for the first half of 2026, and it also reported Phase I updates for LAE102 and the start of Phase I dosing for LAE103 in Australia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4cVM64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232198","title":"Laekna Inc -  Loss for Year RMB229.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232198?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:43","pubTimestamp":1773830589,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4050ZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618026246","title":"Laekna Says Obesity Drug Shows Signs of Lean Body Mass, Reduced Fat in Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2618026246","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618026246?lang=en_us&edition=fundamental","pubTime":"2026-03-10 10:41","pubTimestamp":1773110477,"startTime":"0","endTime":"0","summary":"Laekna  completed the phase 1 single ascending dose study of LAE102, which showed signs of increased lean body mass and reduced fat mass in women, according to a Hong Kong bourse filing Tuesday.After 29 days of treatment, subjects who received the company's drug exhibited a 5.06% increase in mean lean body mass and a 0.12% decrease in mean fat mass from baseline.The study demonstrated a favorable safety profile, with no serious adverse events.The firm said the results add to a \"growing body of data\" supporting the drug's use to treat cardiometabolic diseases. The company is currently planning phase 2 trials of the medicine.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146990437","title":"Laekna-B (02105.HK): Phase I U.S. SAD Study of LAE102 Delivers 5.06% Lean-Mass Gain and Fat-Mass Reduction Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=1146990437","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146990437?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:22","pubTimestamp":1773102178,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (stock code 02105, listed as Laekna-B) released voluntary topline data indicating that its internally discovered monoclonal antibody LAE102 achieved clinically relevant body-composition...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101063129","title":"LAEKNA-B (02105) Reports Encouraging Muscle-Building and Fat-Reducing Trends from US Phase I SAD Study of LAE102","url":"https://stock-news.laohu8.com/highlight/detail?id=1101063129","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101063129?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:20","pubTimestamp":1773102030,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) announced the successful completion of the Phase I Single Ascending Dose study of LAE102 in the United States, conducted in collaboration with Eli Lilly. The US SAD study was a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":82,"code":"91000000","status":"200"}]}}